Linking payment to health outcomes: A taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturers-Reference-Cited by-同舟云学术

Linking payment to health outcomes: A taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturers

Published:2010-08 Issue:3 Volume:96 Page:179-190
ISSN:0168-8510
Container-title:Health Policy
language:en
Short-container-title:Health Policy

Author:

Carlson Josh J.,Sullivan Sean D.,Garrison Louis P.,Neumann Peter J.,Veenstra David L.

Publisher

Elsevier BV

Subject

Health Policy

Reference40 articles.

1. Pricing pills by the results;Pollack;New York Times,2007

2. Coverage options for promising technologies: Medicare's ‘coverage with evidence development’;Tunis;Health Affairs (Project Hope),2006

3. Evidence Review Group Report commissioned by the NHS R&D HTA Programme on behalf of NICE: bortezomib for the treatment of multiple myeloma patients;Green,2006

4. Shared scheme for assessing drugs for multiple sclerosis: dealing with uncertainties about cost effectiveness of treatments is difficult problem;Chadwick;British Medical Journal (Clinical Research Edition),2003

5. Shared scheme for assessing drugs for multiple sclerosis: cost effective provision of effective treatments for multiple sclerosis;Napier;British Medical Journal (Clinical Research Edition),2003

Cited by 217 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. It Takes 2 to Tango. Setting Out the Conditions in Which Performance-Based Risk-Sharing Arrangements Work for Both Parties;Value in Health;2024-08

2. Illustrating the Financial Consequences of Outcome-Based Payment Models From a Payers Perspective: The Case of Autologous Gene Therapy Atidarsagene Autotemcel (Libmeldy®);Value in Health;2024-08

3. Can SMA Innovative Treatments Be Reimbursed? A Rapid Review;Iranian Journal of Pediatrics;2024-07-24

4. Creating win-win-win situations with managed entry agreements? Prioritizing gene and cell therapies within the window of opportunity;Drug Discovery Today;2024-07

5. The Value of Flexible Vaccine Manufacturing Capacity: Value Drivers, Estimation Methods, and Approaches to Value Recognition in Health Technology Assessment;PharmacoEconomics;2024-05-31